Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 2018-2019 Fluzone and Flublok Influenza Vaccines
NCT03617523Phase 4Completed
- Sponsor
- Sanofi
- Start
- Sep 2018
- Primary completion
- Nov 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated), influenza B virus (B/Massachusetts/2/2012) recombinant hemagglutinin, trivalent inactivated influenza vaccine high-dose in influenza, sponsored by Sanofi. Started Sep 2018; status: completed.
02
Drugs
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)influenza B virus (B/Massachusetts/2/2012) recombinant hemagglutinintrivalent inactivated influenza vaccine high-dose
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03617523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617523.